LNTHNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Lantheus Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$99.92+0.22 (+0.22%)
Close on Oct 19, 2026
- Market cap
- $6.75B
- P/E (TTM)
- 24.2
- Dividend yield
- –
Share price
+$44.32 (+79.71%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Lantheus Holdings, Inc. grew revenue 2.3% to $1.56B over the twelve months to Jun 30, 2026. Operating income fell 30.9% to $302.34M, moving the operating margin from 28.8% to 19.4%.
Revenue
$1.56B
+2.3% vs. a year earlier
Operating income
$302.34M
-30.9% vs. a year earlier
EPS, diluted
$4.13
+9.5% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $6.75B
- P/E ratio
- 24.2
- Price to sales
- 4.33
- Price to book
- 5.14
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $1.56B
- Net income
- $275.31M
- EPS, diluted
- $4.13
- Book value per share
- $19.43
- Diluted shares
- 68M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
$1.56B+2.3% YoY
Gross profit
$936.02M-3.4% YoY
Operating income
$302.34M-30.9% YoY
Net income
$275.31M+1.6% YoY
EPS, diluted
$4.13+9.5% YoY
Free cash flow
–
Reported periodTrailing twelve months